Idogen signs strategic collaboration agreement with contract research companies
Idogen AB (publ) has signed a strategic collaboration agreement with two contract research organizations (CRO), Klifo and 4Pharma, which will together with Idogen run the clinical phase 1/2a study with IDO 8, a new cell therapy for patients with severe hemophilia who have developed antibodies to their treatment with coagulation factor VIII. The collaboration agreement applies to all testing centers in Europe where the study will be conducted. Idogen's tolerogenic cell therapy treatment IDO 8 aims to create tolerance for factor VIII and thus enable ongoing substitution treatment with